HighTower Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

HighTower Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$860K	Buy	39,355 +2,324	+6%	+$48.3K	﹤0.01%	2339
2026 Q1	$865K	Buy	37,031 +18,091	+96%	+$393K	﹤0.01%	2289
2025 Q4	$398K	Buy	18,940 +1,517	+9%	+$26.5K	﹤0.01%	2815
2025 Q3	$268K	Buy	+17,423	New	+$228K	﹤0.01%	3137
2021 Q4	–	Sell	-10,741	Closed	-$207K	–	3465
2021 Q3	$207K	Buy	+10,741	New	+$179K	﹤0.01%	2686

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

HighTower Advisors's SNDX Position: Q2 2026 in Review

HighTower Advisors increased its Syndax Pharmaceuticals (SNDX) stake by 6.3% in Q2 2026, buying an estimated $48.3K and bringing the position to 39,355 shares worth $860K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

HighTower Advisors first reported a position in SNDX in Q3 2021 and has held it in 5 quarters since. The position peaked at $865K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

HighTower Advisors held 39,355 shares of Syndax Pharmaceuticals worth $860K as of Q2 2026.
HighTower Advisors bought 2,324 Syndax Pharmaceuticals shares in Q2 2026, an estimated $48.3K.
Syndax Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2339 holding.
HighTower Advisors first reported a position in Syndax Pharmaceuticals in Q3 2021 and has held it in 5 quarters since.
HighTower Advisors's Syndax Pharmaceuticals position peaked at $865K in Q1 2026.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.